Maestros Electronics Share Price Target 2025, 2026, 2030, 2040, 2050
It is an Indian company which makes medical devices, telemedicine tools, and products. They work in areas like heart care, women’s health, emergency care, and disease management. The company creates products such as ECG machines, patient monitors, defibrillators, pulse oximeters, fetal monitors, and telemedicine systems to help improve healthcare. They also provide services for financial services, banking, and public systems. It uses new technology and focuses on developing its products.
- 1 What is Maestros Electronics Ltd NSE: METSL?
- 2 Share Price Target Tomorrow
- 3 Maestros Electronics share price Target 2025
- 4 Maestros Electronics Share Price Target 2026
- 5 Share price Target 2027
- 6 Share price Target 2028
- 7 Share price Target 2029
- 8 Maestros Electronics Share Price Target 2030
- 9 Share price Target 2040
- 10 Share price Target 2050
- 11 Should I buy Maestro’s Electronics stock?
- 12 Maestros Electronics earnings results
- 13 Is Maestro’s Electronics stock good to buy? (bull case & bear case)
- 14 Conclusion
- 15 FAQs
What is Maestros Electronics Ltd NSE: METSL?
Maestros Electronics & Telecommunications Systems was set up in 1991 and is situated in New Delhi, India. It focuses on making medical electronics, telecom products. It designs and builds a wide range of items, such as communication equipment, electronic systems, ECG machines, patient monitors, defibrillators, pulse oximeters, fetal monitors and devices used in industries like defence, railways, and public safety. These products have made the company well-known for being reliable and using the latest technology.
At the beginning of this year, the stock reached its all-time high price. But the price could not sustain there and fell rapidly. The stock continuously made a lower low and fell. At the current time, the company is improving its financials, and the stock is also recovering. For the buying opportunity, you have to be very alert, as shown very strong bearish move, so consider multiple confirmations, analyse the company before investing.
Day | Minimum Price (Rs) | Maximum Price (Rs) |
Tomorrow | -6 | +15 |
It is one of the leading medical equipment companies in India. It helps doctors and hospitals for heart patients, pregnant women, and people in critical condition. They provide a wide range of useful medical devices like monitors, ECG machines, defibrillators, oxygen checkers, baby monitors, stress test machines, and more. It always improving and creating new ideas to keep customers happy. They focus on making advanced technology through their research. They build high-quality products that hospitals and doctors need. In 2025, its share price target would be ₹286, as per our analysis.
By our prediction, its share price would be between ₹119 to ₹286 in 2025.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2025 | 119 | 286 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 174 | 262 |
February | 158 | 209 |
March | 138 | 185 |
April | 135 | 199 |
May | 124 | 205 |
June | 119 | 213 |
July | 132 | 232 |
August | 147 | 249 |
September | 164 | 260 |
October | 187 | 266 |
November | 200 | 270 |
December | 231 | 286 |
It focuses on medical devices, telemedicine, and financial services. The company has shown revenue growth, but it has faced challenges with high debtor days, this has improved recently. Its return on equity is low, and the company doesn’t pay dividends. Also, the promoter’s stake in the company has decreased over the years. But the company has also significantly reduced its debt, making it more financially stable. In 2026, its share price target would be ₹434, as per our analysis.
By our prediction, its share price would be between ₹231 to ₹434 in 2026.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2026 | 231 | 434 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 231 | 297 |
February | 252 | 309 |
March | 269 | 314 |
April | 275 | 323 |
May | 270 | 330 |
June | 274 | 349 |
July | 280 | 364 |
August | 287 | 378 |
September | 290 | 388 |
October | 300 | 397 |
November | 327 | 412 |
December | 361 | 434 |
They focus on discovering and using new technologies in electronics systems and software to create important and advanced products for the healthcare field. Their mission is to provide healthcare services that are not only modern and affordable but also fully meet the needs of doctors and patients. They aim to deliver products that work well, are reliable, and come with excellent service and support. In 2026, its share price target would be ₹582, as per our prediction.
Its share price would be between ₹361 to ₹582 in 2027, as per our analysis.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2027 | 361 | 582 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 361 | 440 |
February | 372 | 449 |
March | 387 | 456 |
April | 398 | 464 |
May | 409 | 470 |
June | 425 | 487 |
July | 435 | 500 |
August | 451 | 511 |
September | 459 | 534 |
October | 469 | 551 |
November | 487 | 568 |
December | 531 | 582 |
The company designs, develops, and makes healthcare products. They offer a variety of products, including patient monitors, ECG machines, defibrillators, pulse oximeters, fetal monitors, and stress test systems. The company has advanced research and manufacturing facilities in Mumbai, India, where they create products. Their main focus is on two areas, which are electronics & Instrumentation (E&T) and Telemedicine. In 2028, its share price target would be ₹734, as per our prediction.
Its share price would be between ₹531 to ₹734 in 2028, as per our analysis.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2028 | 531 | 734 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 531 | 593 |
February | 552 | 618 |
March | 569 | 627 |
April | 570 | 638 |
May | 564 | 647 |
June | 579 | 658 |
July | 587 | 664 |
August | 598 | 670 |
September | 621 | 679 |
October | 630 | 689 |
November | 657 | 711 |
December | 681 | 734 |
The company uses the latest technology and communication tools. Some of the products it sells include stress test machines, telemedicine equipment, ECG machines, and patient monitors. It also offers products for mothers and babies, like fetal monitors and pulse oximeters, as well as products for home care and critical care. Most of the company’s income comes from the Telemedicine part of the business. In 2029, its share price target would be ₹880, as per our analysis.
By our prediction, its share price would be between ₹681 to ₹880 in 2029.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2029 | 681 | 880 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 681 | 747 |
February | 698 | 756 |
March | 700 | 768 |
April | 697 | 779 |
May | 705 | 787 |
June | 718 | 798 |
July | 725 | 810 |
August | 737 | 825 |
September | 749 | 839 |
October | 768 | 854 |
November | 788 | 868 |
December | 800 | 880 |
The company has made a strong brand value in India’s healthcare market by making different medical devices. These include important equipment like defibrillators, ECG machines, and pulse oximeters, which are used in hospitals across India. The company also works in telemedicine, providing systems that allow doctors to monitor patients and communicate with them from a distance. In 2030, its share price target would be ₹1030, as per our analysis.
By our prediction, its share price would be between ₹800 to ₹1030 in 2030.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2030 | 800 | 1030 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 800 | 889 |
February | 838 | 900 |
March | 835 | 914 |
April | 844 | 925 |
May | 840 | 937 |
June | 859 | 942 |
July | 870 | 957 |
August | 879 | 963 |
September | 898 | 975 |
October | 912 | 988 |
November | 934 | 1010 |
December | 958 | 1030 |
The company has stayed ahead in the industry that depends more on advanced technology. It makes products not only for healthcare but also for important areas like defence, railways, and public safety. The company focuses on combining electronics with communication tools, making it a good provider of affordable, high-quality services for both private and public projects. As India invests more in healthcare, its market opportunities are growing, offering strong chances for long-term success. In 2040, its share price target would be ₹2262, as per our prediction.
Its share price would be between ₹2040 to ₹2262 in 2040, as per our analysis.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2040 | 2040 | 2262 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 2040 | 2089 |
February | 2054 | 2099 |
March | 2069 | 2124 |
April | 2077 | 2139 |
May | 2060 | 2155 |
June | 2069 | 2170 |
July | 2087 | 2188 |
August | 2098 | 2200 |
September | 2118 | 2220 |
October | 2127 | 2235 |
November | 2120 | 2251 |
December | 2159 | 2262 |
The company’s early investments to improve its finances and offer more products have given it a strong performance now. They always research for a good and effective device to improve healthcare, especially in places with limited access to medical services. With a focus on developing tools like AI and telemedicine, the company is expected to grow and take advantage of opportunities in the healthcare market, both in India and worldwide. In 2050, its share price target would be ₹3855, as per our analysis.
By our prediction, its share price would be between ₹3590 to ₹3855 in 2050.
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2050 | 3590 | 3855 |
Month | Minimum Price (Rs) | Maximum Price (Rs) |
January | 3590 | 3674 |
February | 3604 | 3688 |
March | 3619 | 3698 |
April | 3632 | 3722 |
May | 3649 | 3731 |
June | 3674 | 3745 |
July | 3680 | 3768 |
August | 3700 | 3781 |
September | 3711 | 3798 |
October | 3710 | 3812 |
November | 3724 | 3824 |
December | 3742 | 3855 |
Should I buy Maestro’s Electronics stock?
Year | Minimum Price (Rs) | Maximum Price (Rs) |
2025 | 119 | 286 |
2026 | 231 | 434 |
2027 | 361 | 582 |
2028 | 531 | 734 |
2029 | 681 | 880 |
2030 | 800 | 1030 |
2040 | 2040 | 2262 |
2050 | 3590 | 3855 |
It could be a good option for long-term investors, especially those interested in healthcare and telemedicine. The company faces some challenges, like low profits, high debt, and no dividends, but it’s working on new medical devices and expanding into areas like defence and railways, which could help it grow. Its products, like ECG machines and defibrillators, are in demand in India’s healthcare market. While the stock might be a bit unpredictable in the short term, long-term could be a good decision as the company improves financially and develops new products. It’s important to analyse the company’s progress before deciding to invest.
Maestros Electronics earnings results
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
Sales + | 13.54 | 47.55 | 11.15 | 24.60 | 33.29 | 35.21 |
Expenses + | 11.94 | 39.06 | 10.11 | 20.93 | 27.37 | 28.63 |
Operating Profit | 1.60 | 8.49 | 1.04 | 3.67 | 5.92 | 6.58 |
OPM % | 11.82% | 17.85% | 9.33% | 14.92% | 17.78% | 18.69% |
Other Income + | 0.47 | 0.96 | 1.48 | 1.26 | 2.24 | 2.26 |
Interest | 1.10 | 1.37 | 0.46 | 0.52 | 0.80 | 0.60 |
Depreciation | 0.45 | 0.36 | 0.37 | 0.39 | 0.45 | 0.43 |
Profit before tax | 0.52 | 7.72 | 1.69 | 4.02 | 6.91 | 7.81 |
Tax % | 32.69% | 26.94% | 25.44% | 25.87% | 28.51% | |
Net Profit + | 0.35 | 5.64 | 1.25 | 2.98 | 4.94 | 5.59 |
EPS in Rs | 0.67 | 10.24 | 2.27 | 5.41 | 8.97 | 10.14 |
Dividend Payout % | 0.00% | 0.00% | 22.04% | 0.00% | 0.00% |
Key Metrics
TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
15.31 | 3.00 | — | 28.23 | 7.76 | 2.18% |
Peers & Comparison
Stock | PE Ratio | PB Ratio | Dividend Yield |
Maestros Electronics & Telecommunications Systems Ltd | 18.56 | 3.00 | — |
Bharat Electronics Ltd | 56.11 | 13.68 | 0.72% |
Honeywell Automation India Ltd | 60.32 | 8.39 | 0.29% |
PG Electroplast Ltd | 201.12 | 26.10 | 0.02% |
Is Maestro’s Electronics stock good to buy? (bull case & bear case)

Bull Case:
- It has been showing steady growth in sales and profits.
- The company benefits from positive trends like green technology and IoT.
- The company has reduced its debt and is nearly debt-free.
- The time it takes to collect payments (debtor days) has improved from 235 to 172 days.
Bear Case:
- The return on equity is low at 12.3% over the last 3 years.
- It is not paying the dividend.
- The company has high debtors of 172 days.
- Promoter holding has decreased over the last 3 years: -8.22%
Conclusion
The company has faced some problems, like low profits, high debts, and not paying dividends, but it has been growing in sales and profits. It has also reduced its debt and is expanding into areas like defence and public safety. The company focuses on making advanced healthcare products, and there’s a growing demand for telemedicine. Investors should look at the company’s financials and the market carefully before deciding to invest.